r/ELTP_Stock

I've gotten a number of DMs asking about investment advice, stocks I like, or what I do for a living. I figured I'd share an important lesson that I learned, and that if I had learned it earlier it would have both made me money, and more importantly saved me from losses.

For background, I am not a financial advisor. I'm a serial entrepreneur who built a million dollar company in my early twenties, lost everything, went back to school, and then took my lessons from my losses and rebuilt from the ground up. I own multiple companies now, almost all started by myself, but I have also bought and sold companies as well. I don't think school is "necessary" for success and I think you will get out of it what you put in to it, but I'm still very glad I went back regardless of whether or not it contributed to financial successes.

When I was young and I would talk with friends about business and business ideas, we tended to discuss an idea, a concept, or an industry. Whoever had the best business idea, we would then talk about "doing" that idea. It never went anywhere though, and eventually I learned the first part of the "Who" lesson unintentionally. They never followed through, and I would be frustrated that it was all just talk. My success started when I just started building a business for myself. I didn't really put much thought in to it other than giving myself kudos for "doing" it.

It wasn't until I rebuilt everything, had sustainable success, and was then able to invest in other things, ventures, and people that the lesson hit home. The things and people that I invested in that did poorly had NOTHING to do with the idea or the product. They were actually all great. The one common denominator with an investment going poorly was WHO I invested in or with. The wrong people will give up when it gets tough (and it ALWAYS get tough), they celebrate too early, they clock in and clock out. The right people just have that "it" in them. Je na sais quoi is a good term from French that means something along the lines of "that thing you can't quite put your finger on" (I don't speak French, but I'm close enough and if I'm not you get the meaning). The right people don't talk - they execute. They don't celebrate the lead, they celebrate the close. A 40 hour work week is part time for them. And most importantly, they do NOT have "quit" in them. When it gets tough, they dig their heels in further. They will literally do everything in their power to move the world around them instead of being moved by the world when it comes to their business.

How can you apply this to stocks? I'll give you two examples of CEO's (Who's) that I've invested in and one that I got wrong by realizing it too late, and one that I got right by realizing it early. Before I get in to them though, I want to clarify one point about this lesson. This is identifying WHO is a good CEO/partner/friend, that should lead to a good investment. This is NOT identifying who is a good PERSON. I think Steve Jobs was a horrible person and incredibly unethical. I think he was a ruthless thief...but damn was he an incredible CEO.

Case #1: Elon Musk and Tesla

When I first started reading about Elon, something seemed off about him. I thought he was selling BS and I didn't want any part of it. I completely missed Tesla because of that. It wasn't until around 2017/18 that my mind started to change about him. He was being heavily shorted and he made some comment about putting a bed in that Tesla factory until he got production to where he wanted. That got my attention and so I started paying attention more to WHO he was. I know this is Reddit and most people hate him on here, but all I saw after that was someone who would stop at nothing to execute on his vision. I probably should have made a more serious investment in Tesla back in 19/20, but I thought I missed the boat. Luckily, I was able to get in Space X about a year and a half ago. I personally think Space X will explode out of the gates (they just signed a $12 Billion compute deal with Google a day or two ago), but I plan to hold long term. Love him or hate him - I think he will go down as one of the greatest operators in history and executes on plan unlike anything I have ever seen.

Case #2: Nasrat Hakim and Elite Pharmaceuticals

I was working on a client's deal who was heavily invested in ELTP and his shares were around 25 or 26 cents a share back in 2017. I looked at the company and it was just a hot mess. A bunch of hopium around a technology that introduced an agitant to pharmaceuticals that would burn your nose and throat if you tried to crush them while using them to get high. The technology was a good IDEA, but it didn't get FDA approval and they had almost no revenue (I think it was sub $1 million at the time.) The client didn't take the advice and I would just look at it every few months as it dropped from 25 to 20 and eventually all the way down to 3 cents.

Then something amazing happened - ELTP started growing revenue and I believe they became cash flow positive around 2020 or 2021. You never really see that from a company that looks like it is on the verge of bankruptcy - especially a company on the OTC. I started reading everything I could on the C-suite. Nasrat impressed the hell out of me. An attorney first and then CEO, he made some incredibly shrewd decisions. He pulled out of all opioids during the massive litigation that was starting around the country against Purdue and other opioid companies. He changed the direction of the company from an "all or nothing" moonshot, to safe and steady generic manufacturer. Then he started negotiating deals, getting shareholders access to larger and larger revenue producing drugs. Lannet Pharma was once a $3 billion market value client of Elite's (and a hopeful buyout partner), was making a move to cut Elite out of the manufacturing side of their deal. Nasrat pivoted and hired Kirko Kirkov to develop an internal sales team. Kirkov was a brilliant acquisition. Kirkov sold more in 1 month than Lannett sold for Elite in a whole year. In another brilliant move, Nasrat sold off 3 drugs to a competitor for some much needed cash, but, at the time, no one knew the details of that full agreement. Nasrat had put a buyback clause in the agreement for the same price Elite was paid, but since he bought it back after the massive inflation post Covid, he essentially was able to buy all the drugs back for around a 25% discount. Due to all of these factors, I really believed in the "Who", and I started acquiring a massive amount of shares. This time, I was proud to have assessed the "Who" so early that I was able to buy shares at the 3 to 7 cent mark. I did have one MAJOR concern though, and it was a big one. The CFO, Carter Ward. My fear when investing in stocks as opposed to real estate deals is that I can never be 100% sure someone isn't cooking the books. This was a tiny company in a lot of trouble, and Carter left the company. That made me very concerned that what if the reason he left was because there was something he didn't like in the books? I've been in a similar situation myself during a stint as a CFO and I know from that experience that when something doesn't look good in the books, it is NOT a good feel and your goal is to get as far away as possible from problematic books. So, as Elite was going through various CFOs in the aftermath, it was making me feel worse and worse. The golden lining was the final moment for me that made me feel great about my investment. Carter Ward came back to ELTP. No CFO would come back to books that had problems in them. It was actually a better sign than if he had just stayed.

Elite has a major date coming up on June 11th where the judge is pushing for an outcome on a patent dispute between ELTP and Purdue. The judge told Purdue to either work out an agreement or he would recommend Elite to file for dismissal, which I read as, "Games over. Figure it out or I'm dropping the case because Purdue doesn't even exist anymore." Closely following that date, ELTP has their annual earnings which will guaranteed be another record breaking year (they broke the record at the 9 month mark already). Top it off with the filing last week of a $26 Billion drug, which, by the estimates of one of the biggest cynics on this board, would be an approximate increase of revenues of about $600 million and ELTP is sitting pretty for an eventual buyout (they hired Jeffries about 10 months ago for M&A) or an uplisting/Spac merger.

TLDR: Who you invest in matters more than what and I'm high on both Space X and ELTP and for those who haven't seen any of my prior posts, I am heavily invested in both.

Long read, but hope it helps give some of you a perspective that I think is extremely important when putting your money in anything.

What’s the best place to purchase Elite stock?

Everyone here that bought over M and A hype is learning a lesson now.

I warned everyone 3 months ago to not follow this guy. He talks like he’s in his early 20s. He got lucky and thinks he knows what he’s doing.

Move on from this shit stock or be a bag holder. This is the first time a community on Reddit pisses me off enough to write in. You guys are following someone who talks with 100% conviction on an OTC. It’s not even the community that is frustrating it’s Wolv himself. Most people trading using Reddit are some 20 year old guys that don’t know the difference between a bull and bear market and Wolv is taking advantage of that . Don’t blindly follow someone who posts using rocket emojis and terms like “Diamond hands”

The 3 Stocks I’m All In On
Fellow degenerates and long-term conviction holders,
I’ve been in this game a long time, grinding through the noise, the bashers, and the paper hands. After years of deep DD and putting my own money where my mouth is, I’ve consolidated heavily into just three plays that I believe have asymmetric upside like nothing else out there right now. These aren’t memes or quick flips for me - they’re positions I’m riding to the moon or bust because the fundamentals, timing, and tailwinds line up perfectly.

Here they are:

1. SpaceX (Pre-IPO Investment)
Look, everyone knows Elon and the boys are building the future of humanity in space. SpaceX isn’t just launching rockets — they’re dominating the entire vertical: reusable heavy-lift vehicles, Starlink global broadband, Starship for Mars missions, and government contracts pouring in. This isn’t some sci-fi dream anymore; it’s operational infrastructure changing industries on Earth while preparing for multi-planetary life.
Pre-IPO access through secondary markets or funds is the way in for those who can. The valuations are already insane, but with Starlink scaling to millions of users and more launches than anyone else combined, the growth trajectory is vertical. This is the one that makes portfolios generational if you get in before the public listing frenzy. I’m all in because space belongs to those who show up first and execute.

2. SPCE (Virgin Galactic)
The meme is right. The time is right. And yes - it’s actually a viable company now.
While SpaceX owns the heavy industrial space vertical, SPCE is carving out the space tourism vertical like no one else. Point-to-point suborbital flights, private astronaut missions, and that “Overview Effect” experience that ultra-high-net-worth individuals are lining up to pay for. They’ve got the flight test program ramping for Q3/Q4 2026, new Spaceships in production, and commercial operations targeted soon after. Tickets at $750k? Demand is there from the right crowd.
This isn’t about competing head-on with Starship…it’s about the premium human spaceflight experience that Branson’s vision pioneered. With the broader space sector heating up (hello, SpaceX IPO buzz spilling over), SPCE has real catalysts ahead. The meme stock energy + actual progress = the setup I’ve been waiting for. I’m loaded up because when the first commercial flights hit, the narrative flips hard. If they actually push technology and go for satellite placement as well? GG

3. Elite Pharmaceuticals (E.L.T.P)
My absolute core conviction play. This company has been executing quietly while the market sleeps on it. Revenue exploding (5000%+ growth since 2020), pipeline expanding, and now this absolute bomb dropped yesterday: They just filed a massive ANDA for a generic anticoagulant targeting a $26 BILLION branded market (per IQVIA data). No generic competition yet, patents/exclusivity still in play on the brand — this could be one of the biggest opportunities in generics we’ve seen.
Elite’s niche focus, manufacturing muscle, and track record on approvals position them perfectly to capture serious market share. Pair that with potential buyout/uplisting timelines (I’m still standing by CEO guidance around Aug 2026 for major moves), and the valuation scenarios are stupid. Moonshot numbers if they execute even half of what’s possible. I’ve been holding since the sub-penny days and adding all the way — this is the deep value + catalyst monster that rewards patience.
These three cover different verticals but share the same theme: massive addressable markets, real technological/execution moats, and timing that feels right in 2026. I’m not diversified anymore — I’m concentrated where I see the biggest edges.
Not financial advice, do your own DD, and never invest more than you can afford to lose. But if you’re reading this and it resonates… welcome to the ride.
Let’s f*cking go. 🚀💊
— Wolvshammy

YAHOOOOOOOO

I used Google NotebookLM to create this report on Elite

Strategic Investment Report: Elite Pharmaceuticals (ELTP)

Date: June 4, 2026 Subject: Fundamental Re-rating and Strategic Valuation Analysis Rating: Authoritative Assessment (Specialty Pharmaceuticals & Biotech)

--------------------------------------------------------------------------------

1. Corporate Profile and Recent Financial Performance

Elite Pharmaceuticals (ELTP) has successfully transitioned from a legacy "penny stock" to a legitimate, profitable specialty pharmaceutical player. This evolution is underscored by a rigorous de-leveraging of the balance sheet, with the company’s debt-to-equity ratio collapsing from 26.7% to 3.8% over a five-year trajectory. This fiscal discipline has provided the "Strategic Stability" required to support a capital-intensive pipeline.

Key Financial Metrics (LTM)

Metric Value
Market Capitalization US$434.05 Million
Revenue (LTM) ~US$140.12 Million
Net Profit (LTM) ~US$43.41 Million
Earnings Per Share (EPS) US$0.04
P/E Ratio 9.68x
Shares Outstanding 1,077,036,442

Financial Health and Liquidity

According to a Simply Wall St fundamental screening, ELTP currently holds a perfect 6/6 Financial Health rating. The company’s liquidity position is exceptionally robust:

* Short-Term Assets: US$96.8 million.
* Total Liabilities: US46.1 million (comprised of US13.2 million short-term and US$32.9 million long-term). Elite maintains the ability to cover all liabilities solely through current assets, reinforcing its status as a debt-free growth entity.

--------------------------------------------------------------------------------

2. Strategic Outlook: Dual-Track M&A and Nasdaq Uplisting

Management is currently executing an overlapping "Two-Option" strategy to realize shareholder value. A critical component of this strategy is the engagement of Jefferies, an investment bank hired at a "7-figure" cost to identify a potential suitor.

Dual-Track Nuance

The CEO, Nasrat Hakim, has clarified that these strategies are not mutually exclusive. While the acquisition remains the primary focus (Option 1), the company has already completed five months of preparation for a Nasdaq Uplisting (Option 2). Critically, even if the Nasdaq process begins, ELTP will continue to actively seek an acquisition suitor.

Timeline Precision

The 12-month agreement with Jefferies is set to expire on June 30, 2026. While no Letter of Intent (LOI) has been announced, management has signaled a preference to delay a potential sale for "a quarter or two." This is a calculated move to integrate full Lisdex (Generic Vyvanse) revenues and margins into the financials, thereby removing valuation "guesswork" for acquirers.

--------------------------------------------------------------------------------

3. Deep-Dive Valuation: The Anticoagulant Catalyst

The recent FDA acceptance of an Abbreviated New Drug Application (ANDA) for an undisclosed anticoagulant—widely identified as generic Eliquis® or Xarelto®—represents an "imminent blockbuster" event. ELTP has already reported positive bioequivalence results for this drug, significantly de-risking the regulatory path.

The "Kirko" Advantage

Unlike ELTP’s CNS products (Adderall and Vyvanse), this anticoagulant is not a controlled substance. Consequently, the commercial sales team ("Kirko") can market the product with zero distribution limitations, potentially allowing ELTP to double its current revenue base upon launch.

Market Capture and PPS Projection Model

The branded market for this asset is estimated at US26B to US27B. Using the 58.8% margins historically associated with such filings (Post #446,880), we model the following:

Market Capture % Annual Revenue Contribution Total Estimated ELTP Revenue
0.5% Capture US$135 Million US$285 Million
1.0% Capture US$270 Million US$420 Million
2.0% Capture US$540 Million US$690 Million

Projected Price Per Share (PPS) Targets: Using an estimated EPS of US$0.21 derived from the moderate 1.0% capture scenario:

* Sector Average (15x P/E): US$3.15
* High-Growth Premium (25x P/E): US$5.25 (Note: This target is strictly contingent upon a 2.0% capture scenario coupled with a growth-focused valuation multiple).

--------------------------------------------------------------------------------

4. Regulatory and Pipeline Analysis

Management has confirmed an official count of three "big boys"—needle-mover assets—currently in the pipeline to manage institutional expectations.

* Purdue Litigation: A critical patent litigation decision regarding generic OxyContin is expected on June 11. There is significant internal frustration that the FDA has not yet granted "Tentative Approval" despite "zero reason" for a delay; this remains a regulatory bottleneck risk.
* Methadone Hydrochloride Launch: ELTP executed the commercial launch of Methadone Hydrochloride tablets on April 2, 2026, targeting a US$22 million retail market (2025 data).
* Macro Tailwinds: The recent Supreme Court ruling (6-3) striking down broad pharmaceutical tariffs and the subsequent 10% ad valorem surcharge exemption for APIs are significant boons for ELTP’s cost structure and M&A appeal to foreign manufacturers.

--------------------------------------------------------------------------------

5. Management Sentiment and Shareholder Intelligence

The investor community remains bifurcated between "irrational exuberance" and "cautious optimism."
--------------------------------------------------------------------------------

Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic drug product in the class of medications called anticoagulants.
IQVIA reported branded product sales for the twelve months ending March 2026 of $26 billion. There is no generic product on the market, and the brand has unexpired patents and exclusivity listed in the FDA's Approved Drug Products with Therapeutic Equivalence (Orange Book). FDA approval and commercialization of a generic product depend on successful filing, FDA approval and addressing the unexpired patents and exclusivities.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops ...

Just something that I saw pop up and would share. Great to have news and articles before a record breaking earnings call. Grabbed another 500k shares in low 30s. What a steal those are gonna be…

https://s3.amazonaws.com/sec.irpass.cc/2258/0001493152-26-026519.htm

Another unsuccessful week. Is the future bright for this stock?